Blocking TGF-β was shown to enhance the anti-tumor response of T cells, suggesting that patients displaying AGR2 overexpression might benefit from a combination therapy involving immunosuppressants and TGF-β blockers [64]. This evidence concerns the gene AGR2 and neoplasm.